Israel’s PsyRx has developed a radically new treatment for depression. It combines an approved medicine from the SSRI family with a low dosage of ibogaine. PsyRx has just completed a successful lab toxicological safety study for the treatment to help it progress to human trials.

https://www.prnewswire.com/news-releases/psyrx-advances-clinical-trial-exploration-with-successful-completion-of-toxicological-safety-study-in-rats-302098275.html

https://www.psyrx.co/